BIO-TECHNE Corp

Biological Products, (No Diagnostic Substances)

TECH Pharmaceuticals & Biotechnology People in Pharmaceuticals & Biotechnology SEC CIK 0000842023 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$11.31B
156,818,238 shares Covers every share class this company has on file.
Insiders on file
9
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$29.65M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
0.26%
insider-held value divided by market capitalisation

What BIO-TECHNE Corp reports

Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$1.22B
FY2025 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
$73.40M
FY2025 profit for the period, from this company’s own annual XBRL filings to the SEC
Employees
3,000
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at BIO-TECHNE Corp

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against BIO-TECHNE Corp.
Insider Reported role Shares Value Last action
Officers 2
James Hippel CFO 142,722 $10.34M F Shares withheld for taxes Aug 15, 2026 position reported
William Geist President 20,503 $1.49M F Shares withheld for taxes Aug 15, 2026 position reported
Officers who also sit on the board 1
Kim Kelderman Kim Kelderman CEO 48,665 $3.52M F Shares withheld for taxes Aug 15, 2026 position reported
Directors 6
John L. Higgins John L. Higgins Board Member 66,876 $4.84M A Grant or award Oct 30, 2025 position reported
Robert V. Baumgartner Robert V. Baumgartner Board Member 46,503 $3.37M A Grant or award Oct 30, 2025 position reported
Roeland Nusse Board Member 44,559 $3.23M S Open-market sale Aug 25, 2025 position reported
Alpna Seth Board Member 15,411 $1.12M A Grant or award Oct 30, 2025 position reported
Joseph D. Keegan Board Member 15,411 $1.12M A Grant or award Oct 30, 2025 position reported
Julie L Bushman Julie L Bushman Board Member 8,775 $635.6K A Grant or award Oct 30, 2025 position reported

Recent insider transactions

Of the 79 rows we hold, 0 are open-market purchases and 6 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for BIO-TECHNE Corp, newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Aug 15, 2026 Kim Kelderman F Shares withheld for taxes 10,821 $72.40 $783.4K SEC filing ↗
Aug 15, 2026 Kim Kelderman M Option exercise or conversion 21,470 $0.00 $0 SEC filing ↗
Aug 15, 2026 James Hippel F Shares withheld for taxes 4,310 $72.40 $312.0K SEC filing ↗
Aug 15, 2026 James Hippel M Option exercise or conversion 9,779 $0.00 $0 SEC filing ↗
Aug 15, 2026 William Geist F Shares withheld for taxes 1,976 $72.40 $143.1K SEC filing ↗
Aug 15, 2026 William Geist M Option exercise or conversion 6,416 $0.00 $0 SEC filing ↗
Jul 29, 2026 James Hippel F Shares withheld for taxes 51,024 $72.03 $3.68M SEC filing ↗
Jul 29, 2026 James Hippel M Option exercise or conversion 62,068 $47.60 $2.95M SEC filing ↗
Jul 28, 2026 Kim Kelderman F Shares withheld for taxes 28,686 $72.07 $2.07M SEC filing ↗
Jul 28, 2026 Kim Kelderman M Option exercise or conversion 35,000 $47.60 $1.67M SEC filing ↗
May 5, 2026 James Hippel F Shares withheld for taxes 56,955 $56.68 $3.23M SEC filing ↗
May 5, 2026 James Hippel M Option exercise or conversion 62,000 $47.60 $2.95M SEC filing ↗
May 5, 2026 Kim Kelderman F Shares withheld for taxes 23,951 $56.68 $1.36M SEC filing ↗
May 5, 2026 Kim Kelderman M Option exercise or conversion 26,692 $47.60 $1.27M SEC filing ↗
Apr 22, 2026 Kim Kelderman F Shares withheld for taxes 1,363 $58.58 $79.8K SEC filing ↗
Apr 22, 2026 Kim Kelderman M Option exercise or conversion 11,344 $0.00 $0 SEC filing ↗
Apr 22, 2026 James Hippel F Shares withheld for taxes 56,097 $58.58 $3.29M SEC filing ↗
Apr 22, 2026 James Hippel M Option exercise or conversion 62,000 $0.00 $0 SEC filing ↗
Apr 14, 2026 Kim Kelderman F Shares withheld for taxes 32,088 $58.66 $1.88M SEC filing ↗
Apr 14, 2026 Kim Kelderman M Option exercise or conversion 36,500 $0.00 $0 SEC filing ↗
Nov 3, 2025 William Geist F Shares withheld for taxes 4,520 $62.57 $282.8K SEC filing ↗
Nov 3, 2025 William Geist M Option exercise or conversion 9,911 $0.00 $0 SEC filing ↗
Nov 3, 2025 Kim Kelderman F Shares withheld for taxes 2,303 $62.57 $144.1K SEC filing ↗
Nov 3, 2025 James Hippel F Shares withheld for taxes 11,865 $62.57 $742.4K SEC filing ↗
Nov 3, 2025 James Hippel M Option exercise or conversion 13,159 $0.00 $0 SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Subsidiaries — 10 legal entities

Subsidiaries of BIO-TECHNE Corp

10 legal entities named in the subsidiary exhibit filed with this company’s most recent 10-K. . Filing on SEC.gov.

This is not the full list. SEC rules only require a company to name its significant subsidiaries.

What that leaves out

Smaller entities are left out of the exhibit entirely. A short list here means a short exhibit — it does not mean the company owns nothing else. Nothing on this page is inferred: every name below is copied from the filing.

Subsidiaries BIO-TECHNE Corp names in its most recent annual report, with the place each one is organised.
Subsidiary Organised in
Advanced Cell Diagnostics, Inc. California
Asuragen, Inc. Delaware
Bio-Techne China Co. Ltd China
Bio-Techne Ltd. United Kingdom
Cyvek, Inc Delaware
Lunaphore SA Switzerland
Novus Biologicals, LLC Delaware
ProteinSimple Delaware
ProteinSimple Ltd. Canada
Research and Diagnostic Systems Inc. Minnesota
What counts as a subsidiary

A subsidiary is a separate legal entity this company controls; it is not the same thing as a brand, a division or an office. These entities do not file with the SEC in their own right, so there is no separate page to open for them.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from BIO-TECHNE Corp’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from BIO-TECHNE Corp’s own SEC filings multiplied by the closing price we hold for the same stock.